
Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step

Carlsquare Equity Research comments on Biosergen's recently announced rights issue.

[Read the full comment here.](#)

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

Contact

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst
niklas.elmhammer@carlsquare.com
+46 (0)70 898 39 59

Attachments

[Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step](#)